Sensei Biotherapeutics (SNSE) Competitors

$20.32 -0.76 (-3.62%)

As of 02:24 PM Eastern

SNSE vs. EDSA, CNTB, DERM, ASRT, and HURA

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include Edesa Biotech (EDSA), Connect Biopharma (CNTB), Journey Medical (DERM), Assertio (ASRT), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to Edesa Biotech?

Sensei Biotherapeutics (NASDAQ:SNSE) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Sensei Biotherapeutics' return on equity of -83.59% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-69.97%
Edesa Biotech	N/A	-163.57%	-52.54%

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Edesa Biotech had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 3 mentions for Edesa Biotech and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Edesa Biotech's score of 0.30 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Very Positive
Edesa Biotech	Neutral

Sensei Biotherapeutics currently has a consensus price target of $40.00, suggesting a potential upside of 96.89%. Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 65.54%. Given Sensei Biotherapeutics' higher probable upside, equities research analysts plainly believe Sensei Biotherapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edesa Biotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A

Sensei Biotherapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Summary

Edesa Biotech beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Connect Biopharma has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sensei Biotherapeutics' return on equity of -83.59% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-114.89%	-94.01%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

Connect Biopharma presently has a consensus price target of $8.67, indicating a potential upside of 243.92%. Sensei Biotherapeutics has a consensus price target of $40.00, indicating a potential upside of 96.89%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Connect Biopharma is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Connect Biopharma had 12 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 13 mentions for Connect Biopharma and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Connect Biopharma's score of -0.23 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Connect Biopharma	Neutral
Sensei Biotherapeutics	Very Positive

Sensei Biotherapeutics has lower revenue, but higher earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,373.84	-$55.48M	-$1.00	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

Summary

Connect Biopharma beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Journey Medical has higher revenue and earnings than Sensei Biotherapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.73	-$11.43M	-$0.47	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

In the previous week, Journey Medical had 9 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 10 mentions for Journey Medical and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Journey Medical's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Journey Medical	Neutral
Sensei Biotherapeutics	Very Positive

Journey Medical has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

Sensei Biotherapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -18.48%. Journey Medical's return on equity of -46.40% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-18.48%	-46.40%	-13.22%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Journey Medical presently has a consensus price target of $13.00, indicating a potential upside of 110.46%. Sensei Biotherapeutics has a consensus price target of $40.00, indicating a potential upside of 96.89%. Given Journey Medical's stronger consensus rating and higher probable upside, research analysts clearly believe Journey Medical is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Journey Medical beats Sensei Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Assertio?

Sensei Biotherapeutics (NASDAQ:SNSE) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Sensei Biotherapeutics has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A

In the previous week, Assertio had 8 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 9 mentions for Assertio and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Assertio's score of -0.22 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Very Positive
Assertio	Neutral

Sensei Biotherapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market. Comparatively, Assertio has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Sensei Biotherapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-69.97%
Assertio	-34.94%	-38.72%	-13.32%

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 5.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sensei Biotherapeutics currently has a consensus price target of $40.00, suggesting a potential upside of 96.89%. Assertio has a consensus price target of $22.65, suggesting a potential downside of 2.89%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Sensei Biotherapeutics beats Assertio on 8 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Sensei Biotherapeutics' return on equity of -83.59% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-182.40%	-117.49%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.63	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 252.94%. Sensei Biotherapeutics has a consensus price target of $40.00, suggesting a potential upside of 96.89%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

In the previous week, TuHURA Biosciences had 4 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat TuHURA Biosciences' score of 0.65 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Positive
Sensei Biotherapeutics	Very Positive

Summary

Sensei Biotherapeutics beats TuHURA Biosciences on 7 of the 13 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNSE vs. The Competition

Export

Metric	Sensei Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.22M	$3.40B	$6.29B	$12.48B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.22	18.81	20.91	25.60
Price / Sales	N/A	284.65	548.78	75.41
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.38	6.78	9.87	6.72
Net Income	-$21.08M	$24.11M	$3.55B	$333.73M
7 Day Performance	-14.49%	0.22%	-0.24%	0.38%
1 Month Performance	-29.21%	1.08%	1.44%	4.02%
1 Year Performance	198.76%	78.09%	41.01%	36.37%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNSE Sensei Biotherapeutics	2.0899 of 5 stars	$20.32 -3.6%	$40.00 +96.9%	+195.7%	$27.22M	N/A	N/A	40	Positive News Upcoming Earnings
EDSA Edesa Biotech	1.5765 of 5 stars	$15.45 -4.1%	$5.00 -67.6%	+662.0%	$143.15M	N/A	N/A	20	Short Interest Increase
CNTB Connect Biopharma	2.9782 of 5 stars	$2.47 -0.4%	$8.67 +250.9%	+221.9%	$140.17M	$60K	N/A	110	Earnings Report Upcoming Earnings Analyst Revision
DERM Journey Medical	2.552 of 5 stars	$5.18 +1.2%	$13.00 +151.0%	-18.4%	$139.93M	$61.86M	N/A	90	News Coverage Earnings Report Gap Up
ASRT Assertio	1.7922 of 5 stars	$22.16 +2.5%	$19.90 -10.2%	+155.4%	$139.28M	$118.71M	N/A	20	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNSE) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. EDSA, CNTB, DERM, ASRT, and HURA

How does Sensei Biotherapeutics compare to Edesa Biotech?

Summary

How does Sensei Biotherapeutics compare to Connect Biopharma?

Summary

How does Sensei Biotherapeutics compare to Journey Medical?

Summary

How does Sensei Biotherapeutics compare to Assertio?

Summary

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. EDSA, CNTB, DERM, ASRT, and HURA

How does Sensei Biotherapeutics compare to Edesa Biotech?

Is SNSE or EDSA more profitable?

Do insiders and institutionals hold more shares of SNSE or EDSA?

Does the media favor SNSE or EDSA?

Do analysts recommend SNSE or EDSA?

Which has stronger earnings and valuation, SNSE or EDSA?

Which has more volatility & risk, SNSE or EDSA?

Summary

How does Sensei Biotherapeutics compare to Connect Biopharma?

Which has more risk & volatility, CNTB or SNSE?

Do insiders & institutionals believe in CNTB or SNSE?

Is CNTB or SNSE more profitable?

Do analysts rate CNTB or SNSE?

Does the media prefer CNTB or SNSE?

Which has higher valuation & earnings, CNTB or SNSE?

Summary

How does Sensei Biotherapeutics compare to Journey Medical?

Which has better valuation and earnings, DERM or SNSE?

Does the media refer more to DERM or SNSE?

Which has more risk and volatility, DERM or SNSE?

Is DERM or SNSE more profitable?

Do institutionals and insiders have more ownership in DERM or SNSE?

Do analysts rate DERM or SNSE?

Summary

How does Sensei Biotherapeutics compare to Assertio?

Which has higher valuation & earnings, SNSE or ASRT?

Does the media favor SNSE or ASRT?

Which has more volatility & risk, SNSE or ASRT?

Is SNSE or ASRT more profitable?

Do institutionals & insiders have more ownership in SNSE or ASRT?

Do analysts prefer SNSE or ASRT?

Summary

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Is HURA or SNSE more profitable?

Which has better earnings & valuation, HURA or SNSE?

Do insiders and institutionals have more ownership in HURA or SNSE?

Do analysts prefer HURA or SNSE?

Which has more risk & volatility, HURA or SNSE?

Does the media favor HURA or SNSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools